ChartMill assigns a Buy % Consensus number of 86% to INSM. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-11 | TD Cowen | Maintains | Buy -> Buy |
| 2025-12-01 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-11-20 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-31 | UBS | Maintains | Buy -> Buy |
| 2025-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-31 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-31 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-27 | B of A Securities | Maintains | Buy -> Buy |
| 2025-10-14 | UBS | Maintains | Buy -> Buy |
| 2025-10-03 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-02 | TD Cowen | Maintains | Buy -> Buy |
| 2025-09-08 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-03 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-21 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-20 | William Blair | Initiate | Outperform |
| 2025-08-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-14 | Stifel | Maintains | Buy -> Buy |
| 2025-08-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-08-13 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-08-13 | UBS | Maintains | Buy -> Buy |
| 2025-08-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-13 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-08-13 | Jefferies | Maintains | Buy -> Buy |
| 2025-08-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-08 | UBS | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-22 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-17 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-08 | JP Morgan | Maintains | Overweight -> Overweight |
25 analysts have analysed INSM and the average price target is 217.33 USD. This implies a price increase of 10.31% is expected in the next year compared to the current price of 197.01.
The consensus rating for INSMED INC (INSM) is 85.6 / 100 . This indicates that analysts generally have a positive outlook on the stock.